A bibliometric research based on hotspots and frontier trends of denosumab

Denosumab is a monoclonal antibody that targets and inhibits the osteoclast activating factor receptor activator for nuclear factor-κB ligand (RANKL). It has been widely used in the treatment of osteoporosis, giant cell tumors of bone, and in the prevention of malignant skeletal-related events (SREs...

Descripción completa

Detalles Bibliográficos
Autores principales: Ren, Bolin, Ren, Xiaolei, Wang, Lu, Tu, Chao, Zhang, Wenchao, Liu, Zhongyue, Qi, Lin, Wan, Lu, Pang, Ke, Tao, Cheng, Li, Zhihong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527327/
https://www.ncbi.nlm.nih.gov/pubmed/36199692
http://dx.doi.org/10.3389/fphar.2022.929223

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9527327/
https://www.ncbi.nlm.nih.gov/pubmed/36199692
http://dx.doi.org/10.3389/fphar.2022.929223

Ejemplares similares